Dow Jones
30.967,82 -129,44 (-0,42%) Nasdaq
11.322,24 +194,39 (+1,75%) Nikkei 225
26.129,58 -293,89 (-1,11%) EUR/USD
1,0265 -0,0005 (-0,05%) BTC-EUR
19.591,40 -303,49 (-1,53%) CMC Crypto 200
435,52 -4,50 (-1,02%)
Onxeo SA (0NWK.L)
| Chiusura precedente | 0,7305 |
| Aperto | 0,3720 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,3720 - 0,3720 |
| Intervallo di 52 settimane | 0,3720 - 0,3720 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 21,02M |
| Beta (5 anni mensile) | 1,22 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0700 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Onxeo Continues to Strengthen its Board of Directors
Bryan Giraudo, COO & CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company’s Board as independent member Paris (France), Nov. 23, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced the appointment of Bryan Giraudo as independent member of the Board of Directors, repl
- GlobeNewswire
Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector
Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy at Sanofi, join the Company’s Board as independent members Paris (France), Oct. 14, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced the a
